Sangamo Therapeutics Sees Unusually High Options Volume (NASDAQ:SGMO)

Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Get Free Report) was the recipient of some unusual options trading activity on Monday. Investors acquired 11,259 call options on the company. This is an increase of 2,053% compared to the typical daily volume of 523 call options.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. SG Americas Securities LLC boosted its stake in Sangamo Therapeutics by 255.2% during the 3rd quarter. SG Americas Securities LLC now owns 88,542 shares of the biopharmaceutical company's stock valued at $53,000 after purchasing an additional 63,612 shares during the last quarter. Golden State Equity Partners boosted its stake in shares of Sangamo Therapeutics by 22.5% in the 3rd quarter. Golden State Equity Partners now owns 166,265 shares of the biopharmaceutical company's stock worth $100,000 after buying an additional 30,500 shares during the last quarter. Miracle Mile Advisors LLC purchased a new position in shares of Sangamo Therapeutics in the 3rd quarter worth $25,000. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Sangamo Therapeutics by 10.2% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 676,189 shares of the biopharmaceutical company's stock worth $406,000 after buying an additional 62,465 shares during the last quarter. Finally, Vanguard Personalized Indexing Management LLC purchased a new position in shares of Sangamo Therapeutics in the 3rd quarter worth $26,000. Institutional investors own 56.93% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on SGMO. Royal Bank of Canada reiterated a "sector perform" rating and set a $2.00 target price on shares of Sangamo Therapeutics in a research note on Thursday, March 14th. StockNews.com assumed coverage on Sangamo Therapeutics in a report on Tuesday, February 13th. They issued a "sell" rating on the stock. Finally, HC Wainwright reiterated a "buy" rating and set a $5.00 price target (up previously from $3.00) on shares of Sangamo Therapeutics in a report on Tuesday, March 19th. Two research analysts have rated the stock with a sell rating, three have assigned a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat.com, Sangamo Therapeutics presently has a consensus rating of "Hold" and a consensus target price of $4.93.

Sangamo Therapeutics Stock Performance

Shares of NASDAQ:SGMO remained flat at $0.51 during mid-day trading on Monday. The company had a trading volume of 1,266,975 shares, compared to its average volume of 2,210,056. The stock has a market cap of $91.26 million, a PE ratio of -0.35 and a beta of 1.39. Sangamo Therapeutics has a one year low of $0.29 and a one year high of $1.78. The firm's 50-day moving average price is $0.81 and its 200-day moving average price is $0.59.

Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) last issued its earnings results on Wednesday, March 13th. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by ($0.09). The firm had revenue of $2.04 million during the quarter, compared to the consensus estimate of $8.96 million. Sangamo Therapeutics had a negative net margin of 146.30% and a negative return on equity of 82.17%. As a group, research analysts forecast that Sangamo Therapeutics will post -0.54 earnings per share for the current year.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.